Drugs /

ipilimumab

Back to Drugs List
Associated Genetic Biomarkers
Associated Diseases

Overview

Generic Name(s):
ipilimumab
Trade Name(s):
Yervoy
NCI Definition [1]:
A recombinant human immunoglobulin (Ig) G1 monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA4), with immune checkpoint inhibitory and antineoplastic activities. Ipilimumab binds to CTLA4 expressed on T-cells and inhibits the CTLA4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.

Biomarker-Directed Therapies

Clinical Trials

View Clinical Trials for ipilimumab

Ipilimumab has been investigated in 305 clinical trials, of which 271 are open and 34 are closed. Of the trials investigating ipilimumab, 3 are early phase 1 (3 open), 79 are phase 1 (70 open), 58 are phase 1/phase 2 (48 open), 135 are phase 2 (122 open), 3 are phase 2/phase 3 (3 open), 25 are phase 3 (23 open), 1 is phase 4 (1 open), and 1 is no phase specified (1 open).

EGFR Exon 19 Deletion, EGFR L858R, and EGFR L861Q are the most frequent biomarker inclusion criteria for ipilimumab clinical trials.

Melanoma, malignant solid tumor, and non-small cell lung carcinoma are the most common diseases being investigated in ipilimumab clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Ipilimumab
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Ipilimumab
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating ipilimumab and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,931 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
mdx-010, mdx-101, bms-734016, Yervoy, 10200, mdx 010, mdx-ctla4, anti-cytotoxic t-lymphocyte-associated antigen-4 monoclonal antibody, moab ctla-4, ipilimumab (substance), ipilimumab (product), anti-cytotoxic t-lymphocyte-associated antigen-4 monoclonal antibody, moab-ctla-4, monoclonal antibody ctla-4, 720801, ipilimumab, ipilimumab, mdx-ctla-4, mdx010
Drug Categories [2]:
Anti-CTLA4 antibodies, Immunotherapies, Therapeutic antibodies
Drug Target(s) [2]:
CTLA4
NCIT ID [1]:
C2654
SNOMED ID [1]:
R-FC347

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.